Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences (NASDAQ:EXAS) has secured Medicare coverage for its Oncodetect™ molecular residual disease (MRD) test through CMS's MolDX program. The coverage applies to patients with stage II, III, and resectable stage IV colorectal cancer for a five-year period.

The Oncodetect test can track up to 200 ctDNA variants and detect cancer recurrence up to two years earlier than imaging alone. The test's effectiveness is supported by clinical validation studies, including Beta-CORRECT and Alpha-CORRECT trials. This Medicare coverage decision impacts over three million Americans eligible for MRD testing across multiple solid tumors.

Exact Sciences (NASDAQ: EXAS) announced significant advancements for its Oncodetect™ molecular residual disease (MRD) test. The Beta-CORRECT study, to be presented at ASCO 2025, validates the test's effectiveness in predicting colorectal cancer recurrence for stages II-IV. Key findings show patients with ctDNA-positive results demonstrated 24- and 37-fold increased risk of recurrence after therapy and during surveillance, respectively. The company also revealed plans to launch a next-generation version of Oncodetect in 2026, powered by the Broad Institute's MAESTRO technology. This enhanced version will track up to 5,000 patient-specific variants and detect ctDNA levels below 1 part per million, offering improved sensitivity and broader clinical utility. The study included over 400 patients, making it Exact Sciences' largest MRD clinical study to date.

Exact Sciences (NASDAQ: EXAS), a leading cancer screening and diagnostic tests provider, has announced its participation in the upcoming William Blair 45th Annual Growth Stock Conference in Chicago. The company's management will deliver a presentation on Tuesday, June 3, 2025, at 9:40 a.m. ET. Investors can access the webcast through the investor relations section of Exact Sciences' website.

Exact Sciences (NASDAQ: EXAS) will present ten abstracts at ASCO 2025, showcasing advancements in cancer detection and precision oncology. Key highlights include:

The Oncodetect™ molecular residual disease (MRD) test shows promising results from the Beta-CORRECT study for stage II-IV colorectal cancer patients. A partnership with Flatiron Health continues enrollment for evaluating MRD testing across multiple solid tumors.

Their multi-cancer early detection (MCED) research reveals potential to reduce late-stage cancer incidence by >40% and mortality by up to 18% in high-risk groups. The company plans to launch Cancerguard™ EX, their MCED lab-developed test, in H2 2025.

The presentation will also feature new data on the Oncotype DX Breast Recurrence Score® test and Cologuard® test, reinforcing their role in cancer screening and treatment decisions. The Falcon registry study will track 25,000 participants against 50,000 standard-care patients to assess MCED test outcomes.

Exact Sciences (NASDAQ: EXAS) has achieved the 2025 Great Place To Work® Certification™ for the seventh consecutive year in the U.S., while also earning first-time certifications in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The certification is based on confidential employee surveys, with 77% of employees rating Exact Sciences positively - 20 points above the U.S. company average. The recognition evaluates workplace culture, employee experience, and leadership behaviors. According to research, certified workplaces show significant advantages: employees are 93% more likely to look forward to work, twice as likely to receive fair pay and promotions, and job seekers are 4.5 times more likely to find good leadership at certified companies.

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, has announced its upcoming participation in the BofA Securities Health Care Conference in Las Vegas. Company management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 1:40 p.m. ET (10:40 a.m. PT). Investors can access the webcast through the investor relations section of Exact Sciences' website at www.exactsciences.com.

Exact Sciences (NASDAQ: EXAS) reported strong Q1 2025 results with total revenue of $707 million, up 11% year-over-year. The company's Screening revenue grew 14% to $540 million, while Precision Oncology revenue increased 2% to $167 million. Despite progress, the company posted a net loss of $101 million ($0.54 per share).

Key developments include the launch of Cologuard Plus™, a next-generation colon cancer screening test with improved sensitivity and 40% fewer false positives, and Oncodetect™, a molecular residual disease test. The company raised its full-year 2025 guidance, increasing revenue outlook to $3.070-$3.120 billion and adjusted EBITDA to $425-$455 million.

Exact Sciences (NASDAQ: EXAS) will present 15 research abstracts at Digestive Disease Week (DDW) 2025 in San Diego, showcasing data about their Cologuard® colorectal cancer screening test. The presentations will highlight:

• High adherence rates across diverse demographics
• Strong predicted patient preference for Cologuard
• Data from over 500,000 patients
• Research on screening programs under development

The company will host booth sessions led by Jordan Karlitz, discussing CRC screening assumptions and early detection importance. Key research topics include patient test preferences, follow-up colonoscopy adherence patterns, and screening effectiveness across different racial/ethnic groups and healthcare settings. The presentations also include studies on environmental impact and a non-endoscopic Barrett's Esophagus detection test.

Exact Sciences (NASDAQ: EXAS) has launched Oncodetect™, a new molecular residual disease (MRD) test for multiple solid tumors. The test can detect cancer recurrence up to two years earlier than imaging by identifying up to 200 ctDNA variants.

Key features of the Oncodetect test include:

• Ability to detect 1 ctDNA molecule in 20,000 cfDNA molecules
• Provides clear 'Detected' or 'Not Detected' results with quantitative data
• Patients testing positive are 50 times more likely to experience cancer recurrence

The test is validated through the Alpha-CORRECT study with nearly five years of follow-up data for colorectal cancer recurrence. Exact Sciences is working with Medicare for reimbursement coverage and advancing validation studies across multiple solid tumors. The test is now available and targets a potential market of over 3 million eligible American patients.